Abstract
From August 1987 to March 1995, 25 patients with high-grade B cell non-Hodgkin’s lymphoma (NHL) were treated with high-dose therapy (HDT) followed by bone marrow purged with immunomagnetic beads. At the time of transplantation, 20 patients were in sensitive relapse and five in first complete or partial remission. Ten patients had secondary high-grade NHL transformed from low-grade NHL. The HDT consisted of TBI followed by high-dose cyclophosphamide. All patients engrafted, except for two patients with early treatment-related death. Eleven patients relapsed, of whom nine died of lymphoma, and two are alive in new CR. The estimated event-free and overall survivals at 5 years were 40% and 48%, respectively, with a median follow-up of 48 months (range 1–123). Eight of the tumours contained the translocation t(14;18) at the major breakpoint region (MBR) of BCL-2. In these patients the presence of tumour cells in the bone marrow graft before and after purging were assessed by PCR. Four of five patients infused with non-detectable minimal residual disease in their autografts are in complete remission, while two of three patients reinfused with t(14;18) positive cells after purging, experienced a fast and aggressive relapse. As found by others, our data suggest that reinfusion of tumour-free autografts obtained by efficient in vivo purging using chemotherapy before harvesting, and/or by in vitropurging of the stem cell products, influence the patients remission status after HDT.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Blystad, A., Kvalheim, G., Torlakovic, E. et al. High-dose therapy supported with immunomagnetic purged autologous bone marrow in high-grade B cell non-Hodgkin’s lymphoma. Bone Marrow Transplant 24, 865–872 (1999). https://doi.org/10.1038/sj.bmt.1701990
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1701990
Keywords
This article is cited by
-
Autotransplant conditioning regimens for aggressive lymphoma: are we on the right road?
Bone Marrow Transplantation (2007)
-
The role of molecular monitoring in autotransplantation for non-Hodgkin's lymphoma
Bone Marrow Transplantation (2002)
-
High-dose therapy with autologous stem cell transplantation in patients with peripheral T cell lymphomas
Bone Marrow Transplantation (2001)